The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles
Open accessAbstract
Lipid Nanoparticles (LNPs) are a promising drug delivery vehicle for clinical siRNA delivery. Modified mRNA (modRNA) has recently gained great attention as a therapeutic molecule in cardiac regeneration. However, for mRNA to be functional, it must first reach the diseased myocardium, enter the target cell, escape from the endosomal compartment into the cytosol and be translated into a functional protein. However, it is unknown if LNPs can effectively deliver mRNA, which is much larger than siRNA, to the ischemic myocardium. Here, we evaluated the ability of LNPs to deliver mRNA to the myocardium upon ischemia-reperfusion injury functionally. By exploring the bio-distribution of fluorescently labeled LNPs, we observed that, upon reperfusion, LNPs accumulated in the infarct area of the heart. Subsequently, the functional delivery of modRNA was evaluated by the administration of firefly luciferase encoding modRNA. Concomitantly, a significant increase in firefly luciferase expression was observed in the heart upon myocardial reperfusion when compared to sham-operated animals. To characterize the targeted cells within the myocardium, we injected LNPs loaded with Cre modRNA into Cre-reporter mice. Upon LNP infusion, Tdtomato+ cells, derived from Cre mediated recombination, were observed in the infarct region as well as the epicardial layer upon LNP infusion. Within the infarct area, most targeted cells were cardiac fibroblasts but also some cardiomyocytes and macrophages were found. Although the expression levels were low compared to LNP-modRNA delivery into the liver, our data show the ability of LNPs to functionally deliver modRNA therapeutics to the damaged myocardium, which holds great promise for modRNA-based cardiac therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Similar to RNP electroporation, Cas9 mRNA and sgRNA can also be delivered into cells via electroporation or liposome-based vectors (Evers et al., 2022; Yu et al., 2023) to improved genome editing fidelity.”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Evers et al., 2022
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M. L., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,532
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes
Li, Q., Huang, Y., Spencer, C. I., Foley, A., Vedantham, V., Liu, L., Conway, S. J., Fu, J., & Srivastava, D. (2012) · Nature · doi:10.1038/nature11044 · Cited by 1,376
Laflamme, M. A., & Murry, C. E. (2011) · Nature · doi:10.1038/nature10147 · Cited by 1,272
Heart repair by reprogramming non-myocytes with cardiac transcription factors
Song, K., Nam, Y., Luo, X., Qi, X., Tan, W. H., Huang, G. N., Acharya, A., Smith, C. L., Tallquist, M. D., Neilson, E. G., et al. (2012) · Nature · doi:10.1038/nature11139 · Cited by 1,162
Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury
Bersell, K. R., Arab, S., Haring, B., & Kühn, B. (2009) · Cell · doi:10.1016/j.cell.2009.04.060 · Cited by 1,053
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
D’Uva, G., Aharonov, A., Lauriola, M., Kain, D., Yahalom-Ronen, Y., Carvalho, S., Weisinger, K., Bassat, E., Rajchman, D., Yifa, O., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3149 · Cited by 667
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 652
Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
Simons, M., Annex, B. H., Laham, R. J., Kleiman, N. S., Henry, T. D., Dauerman, H. L., Udelson, J. E., Gervino, E. V., Pike, M. C., Whitehouse, M. J., et al. (2002) · Circulation · doi:10.1161/hc0802.104407 · Cited by 646
von Gise, A., Lin, Z., Schlegelmilch, K., Honor, L. B., Pan, G. M., Buck, J. N., Ma, Q., Ishiwata, T., Zhou, B., Camargo, F. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116136109 · Cited by 573
Yanez Arteta, M., Kjellman, T., Bartesaghi, S., Wallin, S., Wu, X., Kvist, A. J., Dabkowska, A., Székely, N., Radulescu, A., Bergenholtz, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720542115 · Cited by 534
Mending broken hearts: cardiac development as a basis for adult heart regeneration and repair
Xin, M., Olson, E. N., & Bassel-Duby, R. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3619 · Cited by 514
Lin, Z., von Gise, A., Zhou, P., Gu, F., Ma, Q., Jiang, J., Yau, A. L., Buck, J. N., Gouin, K. A., van Gorp, P. R. R., et al. (2014) · Circulation Research · doi:10.1161/circresaha.115.303632 · Cited by 403
Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics
Dahlman, J. E., Kauffman, K. J., Xing, Y., Shaw, T. E., Mir, F. F., Dlott, C. C., Langer, R., Anderson, D. G., & Wang, E. T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620874114 · Cited by 335
de Boer, R. A., Keulenaer, G. W. D., Bauersachs, J. K., Brutsaert, D. L., Cleland, J. G. F., Dı́ez, J., Du, X., Ford, P., Heinzel, F. R., Lipson, K. E., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1406 · Cited by 305
Self-citationPkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration
Magadum, A., Singh, N., Kurian, A. A., Munir, I., Mehmood, T., Brown, K., Sharkar, M. T. K., Chepurko, E., Sassi, Y., Oh, J. G., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.043067 · Cited by 289
Vascular endothelial growth factor administration in chronic myocardial ischemia
Harada, K., Friedman, M., López, J. J., Wang, S. Y., Li, J., Prasad, P. V., Pearlman, J. D., Edelman, E. R., Sellke, F. W., & Simons, M. (1996) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1996.270.5.h1791 · Cited by 240
Miyamoto, K., Akiyama, M., Tamura, F., Isomi, M., Yamakawa, H., Sadahiro, T., Muraoka, N., Kojima, H., Haginiwa, S., Kurotsu, S., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.11.010 · Cited by 191
Carlsson, L. G., Clarke, J. C., Yen, C. Y. T., Gregoire, F. M., Albery, T., Billger, M. A., Egnell, A., Gan, L., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 186
Quantitative Assessment of Nanoparticle Biodistribution by Fluorescence Imaging, Revisited
Meng, F., Wang, J., Ping, Q., & Yeo, Y. (2018) · ACS Nano · doi:10.1021/acsnano.8b02881 · Cited by 186
Role of inflammation in the progression of heart failure
Yndestad, A., Damås, J. K., Øie, E., Ueland, T., Gullestad, L. L., & Aukrust, P. (2007) · Current Cardiology Reports · doi:10.1007/bf02938356 · Cited by 177
mRNA-Based Protein Replacement Therapy for the Heart
Magadum, A., Kaur, K., & Zangi, L. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.018 · Cited by 176
Hadas, Y., Vincek, A. S., Youssef, E., Żak, M. M., Chepurko, E., Sultana, N., Sharkar, M. T. K., Guo, N., Komargodski, R., Kurian, A. A., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041882 · Cited by 166
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Jain, R., Frederick, J. P., Huang, E. Y., Burke, K. E., Mauger, D. M., Andrianova, E. A., Farlow, S. J., Siddiqui, S., Pimentel, J., Cheung-Ong, K., et al. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0734 · Cited by 164
Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction
Allijn, I. E., Czarny, B., Wang, X., Chong, S. Y., Weiler, M., da Silva, A. E., Metselaar, J. M., Lam, C. S. P., Pastorin, G., de Kleijn, D. P. V., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.042 · Cited by 156
Self-citationMaximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie · doi:10.1002/ange.201203263 · Cited by 150
House, S. L., Bolte, C., Zhou, M., Doetschman, T., Klevitsky, R., Newman, G., & Schultz, J. E. J. (2003) · Circulation · doi:10.1161/01.cir.0000105723.91637.1c · Cited by 128
Optimizing Cardiac Delivery of Modified mRNA
Sultana, N., Magadum, A., Hadas, Y., Kondrat, J., Singh, N., Youssef, E., Calderon, D., Chepurko, E., Dubois, N. C., Hajjar, R. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.016 · Cited by 114
Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression
Turnbull, I. C., Eltoukhy, A. A., Fish, K. M., Nonnenmacher, M. E., Ishikawa, K., Chen, J., Hajjar, R. J., Anderson, D. G., & Costa, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.193 · Cited by 112
Liu, Y., Tseng, Y.-C., & Huang, L. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0818-1 · Cited by 100
Magadum, A., Singh, N., Kurian, A. A., Sharkar, M. T. K., Chepurko, E., & Zangi, L. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.08.021 · Cited by 86
Intramyocardial stem cell injection: go(ne) with the flow
van den Akker, F., Feyen, D. A. M., van den Hoogen, P., Laake, L. W. V., van Eeuwijk, E. C. M., Hoefer, I. E., Pasterkamp, G., Chamuleau, S. A. J., Gründeman, P. F., Doevendans, P. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw056 · Cited by 84
Self-citationMünter, R., Kristensen, K., Pedersbæk, D., Larsen, J. B., Simonsen, J. B., & Andresen, T. L. (2018) · Nanoscale · doi:10.1039/c8nr07755j · Cited by 84
A Contemporary View on Endothelial Function in Heart Failure
Shantsila, E., Wrigley, B., Blann, A. D., Gill, P. S., & Lip, G. Y. H. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs066 · Cited by 77
Liposome Accumulation in Regions of Experimental Myocardial Infarction
Caride, V. J., & Zaret, B. L. (1977) · Science · doi:10.1126/science.910155 · Cited by 75
Huang, C., Leblond, A., Turner, E. C., Kumar, A. H. S., Martin, K., Whelan, D., O’Sullivan, D. M., & Caplice, N. M. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5006239 · Cited by 70
In vivocardiac reprogramming using an optimal single polycistronic construct: Figure 1
Ma, H., Wang, L., Yin, C., Liu, J., & Li, Q. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv223 · Cited by 63
aYAP modRNA reduces cardiac inflammation and hypertrophy in a murine ischemia-reperfusion model
Chen, J., Ma, Q., King, J. S., Sun, Y., Xu, B., Zhang, X., Zohrabian, S., Guo, H., Cai, W., Li, G., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900424 · Cited by 53
Sultana, N., Hadas, Y., Sharkar, M. T. K., Kaur, K., Magadum, A., Kurian, A. A., Hossain, N., Alburquerque, B., Ahmed, S. M. M., Chepurko, E., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.019 · Cited by 45
Kwekkeboom, R. F. J., Sluijter, J. P. G., van Middelaar, B. J., Metz, C. H. G., Brans, M. A. D., Otto Kamp, B., Paulus, W. J., & Musters, R. J. P. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.020 · Cited by 38
Self-citationRepairing the heart: State-of the art delivery strategies for biological therapeutics
Yang, Q., Fang, J., Lei, Z., Sluijter, J. P. G., & Schiffelers, R. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.003 · Cited by 31
Self-citationMessenger RNA as a Novel Therapeutic Approach
Stanton, M. G., & Murphy-Benenato, K. E. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2016_30 · Cited by 16
Lei, Z., Fang, J., Deddens, J. C., Metz, C. H. G., van Eeuwijk, E. C. M., el Azzouzi, H., Doevendans, P. A., & Sluijter, J. P. G. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00590 · Cited by 7
Self-citation
Research works printed but not linked: 1
- de Wit, 2020, Cellular and molecular mechanism of cardiac regeneration: a comparison of newts, Zebrafish Mammals Biomol., 10
Cited by
Sorted by citations
Off-target effects in CRISPR/Cas9 gene editing
Guo, C., Ma, X., Gao, F., & Guo, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1143157 · Cited by 704
“Similar to RNP electroporation, Cas9 mRNA and sgRNA can also be delivered into cells via electroporation or liposome-based vectors (Evers et al., 2022; Yu et al., 2023) to improved genome editing fidelity.”
BackgroundThe 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 583
Strategies to reduce the risks of mRNA drug and vaccine toxicity
Bitounis, D., Jacquinet, E., Rogers, M. A., & Amiji, M. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00859-3 · Cited by 242
Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis
Tong, L., Zhang, S., Liu, Q., Huang, C., Hao, H., Tan, M. S., Yu, X., Lou, C. K. L., Huang, R., Zhang, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade5041 · Cited by 239
Current research trends of nanomedicines
Liu, Q., Zou, J., Chen, Z., He, W., & Wu, W. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.018 · Cited by 223
Metadata
- Authors
- Evers, M. J. W., Du, W., Yang, Q., Kooijmans, S. A. A., Vink, A., van Steenbergen, M., Vader, P., de Jager, S. C. A., Fuchs, S. A., Mastrobattista, E., Sluijter, J. P. G., Lei, Z., & Schiffelers, R.
- Affiliations
- University Medical Center Utrecht (NL)
- Harbin Medical University (CN)
- Utrecht University (NL)
- Corresponding author
- Schiffelers, Raymond
- ORCID
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 343
- Pages
- 207-216
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W4206915884
- Cited by
- 113
- References
- 48
- Citations by year
- 2026: 19 · 2025: 44 · 2024: 23 · 2023: 20 · 2022: 7
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Controlled Release (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- European Commission (HORIZON2020, 721058, 725229, 825828)
- ZonMw (725229, 116002016)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (16169)
- Ministerie van Economische Zaken, Landbouw en Innovatie
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- lipid nanoparticles, modified mRNA, myocardial ischemia-reperfusion injury, cardiac regeneration, systemic drug delivery, firefly luciferase reporter, Cre reporter mice, cardiac fibroblasts
- MeSH terms
- Animals, Infarction, Liposomes, Myocardium, RNA, Messenger, RNA, Small Interfering, Luciferases, Firefly, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
